Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHAT I FIND PUZZLING: How goofballs love to go into other goofballs threads and opine to no end about mindless drivel. Yet, you've got the #1 individual shareholder of MNMD outside of the insiders who holds 4% of the company AND a founder of MindMed telling you the roof is on fire at MindMed HQ. Dr. Scott Freeman has stated in clear terms that management at MindMed is fumbling and bumbling around with it's clinical trials. Dr. Freeman told you there's a faster way to get to Phase 3 than the current snails pace management is on and there's no logical reason why they shouldn't change course. The current CEO is lethargic with his approach to messaging and management skills. Barrow acts like he's on _______. He's a young guy who likely could care less about taking another 8 years to get past it's 1st Phase 3 clinical trial. Meanwhile, Barrow and the growing Board of Directors will keep getting compensated in real time while you get reverse split up the anus and subsequently diluted to the bone. You're about to cough up 15 for 1 for starters.
WAKE UP PEOPLE!
M$
Can someone please tell me how to go into Expanded Mode for my history of posts?
Thank you,
M$
Unfinished Business
85% of all your posts are at BLOZF.
82% of all your posts at BLOZF are directed at my posts.
Yet, you had the nerve to say...
Sidekick (pigsandsheep/High420)
Is this thing still headed for the NASDAQ as adamantly stated before?
M$
The Exit
Final Shot: 6.5 years and 4 CEO's (Kulwant Malhi, Guy LaTorre, Alfred Wong, Christopher Moreau) later, I finally found The Exit to my journey throughout Dante's Inferno. In that window of time (time is the enemy) I went from being a fan of each CEO to openly expressed fury. My spellbound and hell-bound experience of the Algernon Pharmaceuticals story ends here and now in 3 2 1...
Good Luck & Best Wishes To All Shareholders.
M$
Outro
Capitalization
Issued & Outstanding: 1,983,985
Reserved for Issuance: 624,206
www.thecse.com/en/listings/life-sciences/algernon-pharmaceuticals-inc
M$
Those Cannacord Canadian market maker boys are doing all they can to keep this heap of junk from dropping like a rock with another fake wall at 30 Cents.
M$
I sent the nice lady reporter from buzzfeed who did the article on marijuana breathalyzers back in 2016 (https://www.buzzfeednews.com/article/amandachicagolewis/everyone-wants-a-marijuana-breathalyzer-but-no-one-knows-if) the latest news release by Cannabix. I encouraged her to do a follow up story about the marijuana breathalyzers being pursued by whatever known companies are currently working that angle. I hope to hear back from her in more ways than one.
https://www.amandachicagolewis.com/
M$
Hey Kool-Aid! Oh, Yeah!
That about sums up any hype about receiving Topline data results for a study that was due at minimum a year ago. What we do know is whatever the data suggests it won't be enough to move to Phase 3. The question is whether or not the data is even relevant enough to warrant running another Phase 2 study much less ever getting to a Phase 3 study? What we also know is there is currently zero funds to run a true Phase 2 study powered for stat sig. We also know if such a study were to occur in your lifetime they are planning to go back to Australia where there's a snails pace enrollment rate and a country willing to shut down 100% during pandemics. The covid variants are still out there.
Meanwhile, Christopher Joseph Moreau has the luck of a Death Row inmate. I wouldn't put it past lightning striking twice in Australia for another study stretching out 2 or 3 or more years in the Land Down Under with a lived experience by shareholders the likes of Dante's Inferno. Your leaders have their heads in the sand like Ostriches. They will slow roll giving Bellus Health a billion dollar market cap run for the money to instead pursue massive dilution Phase 1 studies. Anyone thinks Wall Street is interested in that scenario? Where Algernon finds the 8MUSD for everything but a Randomized Double-blind Placebo Controlled Chronic Cough study conducted in North America remains a mystery meat pie in the sky from what I can tell.
Algernon's mystery meat pie pairs well with Kool-Aid.
Bon Appetit
M$
The latest "news release" is an extended pump and dump about more testing with entities they claim they can't name. Hound Labs has already ran thru the same hoops with it's device and "recency of use" science theory. Without actual confirmation of IMPAIRMENT it will not overcome or overwhelm the masses in charge of making the ultimate decisions about whatever devices and theories are thrown at the power that be which includes the courts.
Enjoy the latest 30 Cents gas pump.
M$
"IF YOU WANT A MAP OF HELL DON'T ASK AN ANGEL TO DRAW IT" - Unknown
Algernon Pharmaceuticals is unquestionably a journey through Dante's Inferno. I know, I've been there and back (2015 - 2022). I took all the wrong turns for the exit while chronicling a years long compilation of forked tongue bullshit @ Algernon Pharmaceuticals Inc.
Save Yourself
Reply to smoki: Yeah, the CEO's smile reminded me of a Fruitcake. It had everything - every emotion mixed into it - including denial and deception and dastardly dilution to no end.
Reply to Uncle Buckshot: Yes, they sold another 20% of the company to keep their salaries and bs stock bonuses going for another year and pay their virtual office utility bills at their homes. Where's the money for all the Phase 1's that's surely headed for collosal dilution of shares? It sure ain't through any partnerships, grants, or any other non dilutive means. If you can't sell your story to Wall Street... Oh well!
(Insert rocketships and gas pump emojis here)
M$
It's been a while Uncle buckshot but you have always brought a clear view to this message board. It's long past later for sugarcoating what shareholders have been put through and continue to face. There's nothing civil about the war being waged against you by management @ Algernon. I agree that Moreau is deflecting from IPF/CC results (it's a "pilot" study that doesn't move the needle to phase 3) and continues to pivot to phase 1 studies that will surely continue to dilute the company by multiples on end. Moreau will run the share count right back up as if none of the reverse splits (2 to date) on his watch ever happened. Unfortunately, I do not see the current share price as the bottom. I see sub $1 on the horizon and Algernon remaining in pennyland for the foreseeable future. It's my belief Nasdaq was a fake out to justify a reverse split and subsequently dilute the hell out of the company (an orchestrated whitewash). The one other thing is if the pending and never ending IPF/CC data were thought to move the needle, it would seem management wouldn't have come up way short (45% short) of 2M CAD with their fire sale Public Offering in Canada. I believe their inability to raise cash by telling their pennyland stories is a precursor to bankruptcy potentially in 2023. DMT, CKD, and Cancer combined are not the hot ticket to potentially and exponentially increasing market cap. They are running away from Chronic Cough as if there's a conspiracy between Algernon and some other entity(s) out there >>> They have waged war against their investors by burying there heads in the sand (Australian Ostrich) and marching forward with their pie in the sky plans at phase 1
Peace,
M$
Algernon just sold shares at 1.45 Cents USD + Warrant at 1.45 Cents USD = 2.9 Cent Unit. They struggled to raise 2M CAD. They came away with 1.1M CAD (half-assed). On paper, Algernon remain 8M USD short of cash. The mind's @ Algernon can't complete the task of getting cash or getting to Nasdaq much less "Mars". So what's Mars considered now....a $5 $10 $20 stock? $30 USD is the average break even point if you factor in the 100 to 1 reverse split (You forgot already?). For many, "Mars" is somewhere north of $100 USD. Meaning, there's current 2.8 Million fully diluted shares (2 Million shares + 800 Thousand Warrants). Thus, $100 USD per share = $280,000,000 USD Market Cap.
The problem with getting to "Mars" remains dilution and lack of vision (competency). Once again, Algernon raised 1.1M CAD of 2M CAD with a fire sell @ 1.45 Cents USD share and 1.45 Cents USD warrant (a Unit)! Not even the Canadians are thinking "Mars". Furthermore, Algernon still hasn't dealt with it's need of 8M USD from Wall Street (see multiple SEC F-1/A filings). How much dilution will be added to the equation if Algernon is ever successful with raising another dollar for a dream? What the numbers currently suggest is a capital raise of 8M USD from Wall Street will dilute the shares by a minimum of 2.1 Million shares + 2.1 Million warrants (a Unit) according to the lastest F-1A filed on June 3, 2022.
https://www.sec.gov/Archives/edgar/data/0001642178/000106299322014238/formf1a.htm
If they're ever capable of another capital raise add another 2.1 Million "Units" to the overall equation. The fully diluted shares will then become 2.8M + 4.2M = 7 Million shares fully diluted. Meaning, if "Mars" is somewhere north of $100 per share, Algernon requires a market cap no less than $700,000,000 USD (700MUSD). Now what possibly could get Algernon to a 700MUSD market cap BEFORE the continuation of massive dilution to move multiple pie-in-the-sky Phase 1 studies forward? If you guessed a standalone Randomized Double-blind Placebo Controlled Phase 2 Chronic Cough clinical trial conducted in North America (The Golf Standard), I'd be in 100% agreement with you. As of right now, there is no foreseeable path to Algernon running such a study. Meaning, Algernon is likely to continue diluting shares on the penny exchanges (CSE/OTC) and the likelihood of ever reaching "Mars" will ultimately require a Market Cap in the multi BILLIONS of USD. That's if anyone currently invested is still alive by that time. Your continued journey through time and space (Dante's Inferno) awaits >>>
Of note: What's truly "Mars" for you? When Christopher Moreau told shareholders he was looking to make a "life-changing" difference for shareholders - what do you believe he meant? Given what we know about his character - do you think he'd ever reasonably explain it in public? If what he told you pre-reverse split/consolidation/reorganization (LMFAO) - do you believe a 3 or 4 times ROI is life-changing? A 3 to 4 bagger is what's representative of all the time travel numbers and coordinates above. If a life-changing ROI is thought to be at least a 10 bagger by a few/some/many/all...well take all those numbers above and times them by INFINITY (8). Anyone holding pre split shares would now be incredibly fortunate to just break even. Of course not factoring in the loss of your valuable time in a galaxy of investment opportunities.
M$
my lord...why ? eom ms
You must PROVE IMPAIRMENT in the largest state in the country (California) with a population the size of Canada. There's no way in hell you will convince the majority of the USA to buy into marijuana dui laws that will just assume you're impaired based on arbitrary numbers and science. Until there's a consensus among the scientific community there will not be a sustainable market for a thc breathalyzer. That's assuming a breathalyzer will ever be a scientifically reliable method for determining impairment. To date, all the peer-reviewed scientific data says it is not.
California
§ 23152(a). In California, it is unlawful to drive under the influence of any drug. However, the state must show that the substance impaired the driver, not simply that the driver ingested the drug and then subsequently drove. NOTE: there is no exception in section for lawful users of medical marijuana.
M$
"Impaired driving laws DO NOT require actual impairment."
^Those are words by someone @ yahoo finance^
The Cult of Camp Cannabix...
So you want a thc breathalyzer on the market that doesn't confirm impairment - just a thc breathalyzer to punish people regardless of impairment?
It's further stated "Certain laws do need to be properly enforced."
Sounds a bit like fascism?
Yeah, those are the type of laws we all want on the books and enforced to the fullest extent of the law.
Right?
M$
The fire in Romania (COVID study)
The #1 successful containment in the entire world for COVID in South Korea (COVID study)
The lockdown of the entire country of Australia due to COVID-19 (IPF/Chronic Cough study)
The rejection of funding multiple Phase 1 studies "targeted" to start in Q3 and Q4 2022, by Wall Street and Canadian investors.
The market meltdown and looming global recession unleashing headwinds that could prove to be a fatal/final blow to the existence of Algernon Pharmaceuticals Inc.
Either the CEO & Crew are the absolute unluckiest bunch of people or they're the dumbest bunch of people in the land of biotechs.
I believe they're both unlucky and dumb.
Plus untrustworthy and and and...
M$
Postscript
Bellus Health
Phase 2 Chronic Cough Study completed in 1 year
Billion $ Market Cap @ End of Phase 2
Smart Biotech People!!!
See @ ceo.ca
ceo.ca/blo?f9285b3a5839
M$
In other stroke news, Dr. Mark Williams (Board of Director @ Algernon Pharma|ceuticals Inc) former employer Diamedica Therapeutics, Phase 2/3 stroke clinical trial gets torpedoed by the FDA. Dr. Williams is a coinventor of DM199.
https://www.businesswire.com/news/home/20220706005843/en/DiaMedica-Therapeutics-Announces-Clinical-Hold-of-its-Phase-23-ReMEDy2-Clinical-Trial-for-DM199
OAN: The announcement today of the start of Algernon's DMT stroke study would appear to be a distraction from the still awaited IPF/Chronic Cough Topline data readout. My best guess is the results will be underwhelming. Thus, you're thrown a piece of red meat to push your mind further down the road. If you're told a study will start in one particular quarter, add a couple more quarters to the story and hold onto your @ss.
On with the show this is it.
M$
See @ ceo.ca
ceo.ca/agn?cb3551a009fb
M$
No matter how much jumping up and down ranting and raving management does you must come to grips (wits) with 1 E Z 2 understand fact:
The problem with an alternative facts narrative about Algernon is it will not work on Wall Street. Wall Street experts can clearly see what's historically been going on at Algernon's virtual HQ and it hasn't convinced Wall Street to give Algernon any money from what I can tell in black and white. Another simple fact is Algernon does not have $4M on hand (CAD or US) in addition to the closing of the latest Canadian fire sale public offering. Why anyone would think/post that is just Kookie nonsense. There's nothing in the filed documents at Sedar or SEC that would suggest Algernon is anything but on the brink of bankruptcy.
MANAGEMENT’S DISCUSSION AND ANALYSIS
For the six months ended February 28, 2022 and 2021
Dated April 27, 2022
Re: Liquidity risk
Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company’s objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements. All of the Company’s financial obligations are due within one year.
At February 28, 2022, the Company had a working capital of $1,021,588 compared to working capital at August 31, 2021 of $3,886,947. This included cash and cash equivalents of $1,813,312 (August 31, 2021 - $2,411,163) available to meet short-term business requirements and current liabilities of $1,441,284
(August 31, 2021 - $1,022,314).
Full Stop
^Do the burn rate math. If you're not reading/comprehending the filed documents you're not doing actual due diligence. You're just making sh!t up as you fumble along.
Management raised $900K USD from the Canadian offering after having asked for $9M USD from the American offering. Management also targeted the Canadians for 2M CAD and came away with just over half (1.1M CAD) of their intended goal. Thus far, Algernon is 90% short of the mark for raising capital to pursue it's targeted pipeline of "stuff" moving forward. The question everyone must ask themselves, if not already, is do you want to move the narrative forward based on facts or pure fiction?
Anybody else know who Don is?
M$
Postscript
If management ever gets around to running a study for Chronic Cough they will make it as difficult as possible to reach statistical significance. They will continue to roll Chronic Cough into a study with the sickest of patients by primarily targeting people with Idiopathic Pulmonary Fibrosis. It will make your chances of success exponentially more difficult. They will take whatever information they glean from the next study to spin a story to run a 3rd study likely for Chronic Cough only. I see that as their likely 10 year strategy for Chronic Cough moving forward. Along with slow recruitment in Australia for tax rebates years later when they're back at the public trough begging for loose change to keep the company afloat.
Oh...does anyone believe Algernon will uplist to Nasdaq this year or the next? Your entire destiny now hinges on a journey through hell that's taken 2 years to get to a non statistically significant Topline data readout of 20 patients for IPF/CC. If it's underwhelming data they will overhype it until the Final data readout likely in another 6 months (Q1 2023). My best guess is you will remain on OTC for the foreseeable future. None of the goals set revolving around the 100 to 1 reverse split have come to fruition. A company "reorganization"? rotflmao... it's a pennyland whitewash dudes n dames.
Of note: In the latest filed MDA in April 2022, management stated Final Data for IPF/Chronic Cough was expected in Q2 2022.
It looks like management will be able to continue paying themselves and home utility bills (virtual offices) for a little stretch of the way. 310,000 shares + 310,000 warrants = Units of 1.875 Cents CAD/1.45 Cents USD when you factor in the 100 to 1 reverse split lest you forget.
Carry on...The Fire Sale 4th.
M$
2 New Studies: Detection of THC in Blood or Breath is not Correlated with Impairment.
The studies at the links below were conducted by scientists who primarily disagree with Cannabix's entire premier/platform for marijuana impairment. Both studies were published in Peer-reviewed Scientific Journals. Meaning, global Scientists talking to each other who do not play a bunch of games. If any company attempting to put a breathalyzer in the hands of Law Enforcement as one tool to determine impairment, it will require the Scientific community coming to an agreement. That is what any court in the land will look at to determine the validity of a marijuana breathalyzer being used commercially. Cannabis continued to talk about having a "Court Certified" breathalyzer. If the 2 latest studies hold up, you can bet Cannabis will end up back at the drawing board.
https://norml.org/news/2022/05/26/study-detection-of-thc-in-blood-exhaled-breath-is-not-correlated-with-impairment/
https://hightimes.com/study/study-finds-thc-detected-in-blood-or-breath-does-not-indicate-impairment/
Chronic Cough: 50 Patient Proof of Concept Study Completed in 10 Months in UK.
https://www.businesswire.com/news/home/20220629005372/en/Axalbion-Announces-Positive-Findings-from-Phase-2-Clinical-Study-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist
https://clinicaltrials.gov/ct2/show/NCT04866563
Jacky Smith (Principle Investigator) is on the Advisory Board of both Algernon Pharmaceuticals and Bellus Health, and likely other companies. She's a hired gun for Chronic Cough. It would appear that Algernon is the only company that struggles enormously to get to data results. It has everything to do with location and cheap tricks. Will management ever change their wicked ways?
https://algernonpharmaceuticals.com/medical-and-scientific-advisory-board/
https://bellushealth.com/about-us/our-company/#chronic-cough-cab
"“We look forward to testing AX-8 in this proof-of-concept study, as there are currently no approved treatments for chronic cough. By activating TRPM8, our goal is to decrease the upper airway sensitivity in chronic cough patients, and reduce coughing and throat irritation,” said principal investigator Jacky Smith, MD, professor of respiratory medicine at the University of Manchester, UK."
https://WWW.BUSINESSWIRE.COM/news/home/20211020005271/en/Axalbion-Announces-First-Patients-Treated-in-Phase-2-Clinical-Trial-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist
https://axalbion.com/
M$
See @ ceo.ca
ceo.ca/agn?63ef3efc7944
M$
See M$ FYI @ AGNPF Message Board
STINK TO HIGH HEAVEN
IMO, only a fool would continue sitting on their hands and knees watching their chances at a decent ROI slip away because of ongoing shenanigans @ virtual office HQ. What further shenanigans do you need to endure before taking action, another 100 to 1 reverse split in 2023?
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
I will reiterate once again, your chances of getting any significant ROI will come down to what decision management makes with the proceeds from the Public Offering. If they decide to barrel ahead with Phase 1 studies you are toast for at least the next 5 years. If they do the right and obvious thing, they will take the money and run a Gold Standard Phase 2 study for Chronic Cough in the USA ASAP.
Chronic Cough is the fast track to a billion dollar market cap. Moreau cannot point to any other faster avenue if one even exists with Cancer or Stroke or CKD. They're all long shots far off into the distant future. Chronic Cough is here and now. Strike while the iron is hot (momentum and market interest) and finally give Bellus Health a run for the money versus blowing hot are on webcast claiming Bellus Health is a pure comparison to Algernon Pharmaceuticals.
Prove it in Words and Deeds Christopher Moreau (CEO).
Good Luck To All In All Your Endeavors In Life,
M$
On the issue of the COVID-19 study being FDA approved to move to a Phase 3 clinical trial... PROVE IT.
You're saying it's so because Christopher Moreau said so...LMAO. As I've already stated, that study was not powered for statistical significance. In Moron Moreau's OWN WORDS, he told the market the study would have needed overwhelming data to move to Phase 3. If you believe Algernon had the means/money to run a real Gold Standard - 2000 patient study to try to get to statistical significance, I have a bridge to sell you.
Had they gotten statistical significance from a Gold Standard Phase 2 clinical trial, Algernon would likely have gotten all kinds of financial help to move forward in their efforts. You cannot get around the fact of having been duped by double talk coming from management.
The two COVID-19 studies in South Korea and Romania were both trash @ss studies that had no chance from the outset. As witnessed by South Korea study never getting off the ground (Schleprock). The data coming from the IPF/Chronic Cough study will be recycled into another Phase 2 study maybe, maybe not. Who knows?
On April Fools Day 2021 this news dropped:
www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
At long last, through all the smoke and fire, pain and suffering, blood and guts, I've clearly and convincingly found my exit out of Dante's Inferno (Algernon Pharmaceuticals Inc.). It's been documented here in plain and EZ to understand English. There is no doubt the masses of AGNPF shareholders entered through the doors of purgatory and found themselves fighting like hell. Whatever level of the journey shareholders find themselves in, I hope one day they too will find their peace.
I Have
Have @ It
M$
The Inferno PostScript
Christopher Moreau has controlled the direction of Algernon Pharmaceuticals since Q1 2018. The company purchased a repurposed drugs strategy from Nash Pharmaceuticals in Q4 2018. Of the four leading compounds purchased by Algernon, only one of those drugs have been advanced into a so-called Phase 2 study. The business strategy that you were sold underhandedly led you to believe they could run expeditious Phase 2 studies that would immediately move to Phase 3 given a successful data readout. However, that is not what you were truly sold. The truth is Algernon runs cheap studies in countries outside of North America that are not designed to move beyond Phase 2. Their business model actually requires at minimum twice as many years at Phase 2 than many other biotech companies. IMO, shareholders continue to endure a long drawn out and underhanded scam since becoming Algernon Pharmaceuticals in 2018. In summary, Algernon Pharmaceuticals has taken nearly 4 years to run a study on just one of its originally intended disease targets. It won't be until Q4 2022 or Q1 2023 before you receive a Final Data Readout for IPF/Chronic Cough (an ultra low budget 20 patient study). Algernon has not pursued their repurposed NASH or IBD drugs since their purchase from Nash Pharmaceuticals in 2018. Each being 30% of the overall cost to acquire such drugs. Algernon has only recently decided to pursue CKD with NP-251 (Repirinast), a drug tested preclinical back in 2019.CKD was also 30% of the overall cost to acquire such drugs, which required a 2 to 1 reverse split and subsequent doubling of shares thereafter (dilution on steroids). Sound familiar? Go figure. NP-251 was a Phase 2 entry level drug that is now a Phase 1 entry level drug.
Adding insult to injury, your management team has thrown out the speedy Phase 2 scam and reverted backwards to Phase 1 studies for all drugs in the pipeline. The company has moved backwards. Any claims to start from preclinical advancing directly to Phase 2 clinical trials is now a false and misleading statement. However, don't let that stop Algernon from still claiming it with pipeline graphics and other such ill literature. By the time Algernon Pharmaceuticals ever gets to its very 1st Randomized Double Blind Placebo Controlled Study Powered For Statistical Significance (THE GOLD STANDARD), it will be the year 2025 if you're lucky with Schleprock as your CEO. That's a 7 Year bad luck timeline to get real world data that will determine if your 1st leading compound will make it to a Phase 3 clinical trial. Christopher Moreau peddled the story of you having a 65% chance of success at Phase 2 to move to Phase 3 with both the COVID-19 study and pending IPF/Chronic Cough results. Moreau said that knowing neither of those studies were powered for statistical significance. Meaning, neither of those studied had/have a chance of advancing to Phase 3. You have been royally duped by management. It's incredible the company has not been sued by now. See the list of companies at the following link who ran clinical trials during Algernon's disastrous IPF/Chronic study in Australia.
pact.lungfoundation.com.au/find-a-trial/
You can see Algernon sticking out like a sore thumb when it comes to the Gold Standard for clinical trials. Algernon is a low rank company that peddles cheap penny stock shares and warrants to support insider lifestyles. No more. No less. No foreseeable changes in the future.
Of Note: Christopher Moreau told shareholders in at least one of those scripted webcasts where he spoke to people at other biotech companies and told them he could run Phase 2 studies on the cheap. None of those other biotech companies believed a word that he said. It’s most likely because Christopher Moreau was not talking about running Gold Standard studies like they were. Christopher Moreau was talking in another language. He was talking about running straight up BS studies that merely continue to waste shareholders' valuable time and money before ever running a straight forward clinical trial at Phase 2. You are screwed for at least the next 5 years if Algernon does not pivot ASAP to directly running a Gold Standard Phase 2 study in North America for Chronic Cough. That’s your only reasonable chance at the bogus “65% chance of success” spouted out of the mouth’s of Christopher Moreau (CEO) and Dr. Mark Williams (CSO) .
Schleprock @ The Helm of Algernon Pharmaceuticals Inc.
PostScript II
The Days Of Naivete 5+ Years Ago @ Breathtec Biomedical Inc.
/investorshub.advfn.com/boards/read_msg.aspx?message_id=129824673&txt2find=world
Buy Them All. Bye. M$
Information Anyone Interested In Cannabix Technologies Can Use:
From news release dated September 27, 2021 - "Cannabix devices are in the advanced prototype and pre-clinical testing stage."
From the Global Center for Medical Innovation (GCMI):
Medical device innovation does not come easy, or cheap. Nor should it. The stakes at every level are about as high as they come in innovation of any kind. From Concept to Cure, the seven stages of the medical device development collectively consume as many as seven years or more, tens of millions of dollars or more and no assurance of making it to market. Trust at every stage is critical.
The Seven Stages of Medical Device Development
Research and Development
Preclinical Testing
Permission for Clinical Trial (510(k), IDE – Investigational Device Exemption, PMA – Premarket Notification Application)
Clinical Trials
Manufacturing
Permission to Market
Post Market Requirements
Full Stop
The above information puts into perspective a reasonable expectation of a timeline for Cannabix moving forward. Cannabix is working on what is for all practical purposes a medical device. Which is why they use the terminology - pre-clinical. I wouldn't expect there to be a leapfrog to commercialization/monetization anytime in the near future.
Have @ It
M$
If simple math and management’s expressed plans for the pipeline timeline moving forward does not reasonably explain how expecting a 10,000% Return On Investment (a 100 bagger) is wishful thinking at best - nothing will. I’ve laid out a reasonable expectation of dilution for the foreseeable future as management chases after super long-shot cancer studies and brain surgery (stroke) with a psychedelic drug. A pertinent and smart question to ask is why aren't you asking management what the hell are they doing about running a speedy Phase 2 clinical trial in North America for Chronic Cough ASAP - 1 year from start to finish(?). Sitting back thinking Moreau has it all figured out shall be a detriment to your cause. It’s obvious from past practice that their timelines are not advantageous to your time and money. They own 2% of the current shares and get paid no matter how the stock performs. When/how do you go about holding them accountable? By expecting someone else to do the heavy lifting or voicing your own concerns? It’s called activism. It’s a myth to think you can’t make a difference. The most logical path to maximizing the market cap with the least amount of shenanigans by management (ohhh there will be plenty more if you let them) is throwing all effort/money at Chronic Cough. Simply consider the fact they believed it was OK to spin the company on a dime and throw nearly all of Algernon’s capital at chasing COVID-19 down a black hole. They knew the odds were incredibly stacked against an underpowered study to reach statistical significance to move to a Phase 3 clinical trial. Moreau finally admitted as much in the lead up to the Final Data Report for COVID-19.Moreau beat the drum of success right up until the Final data readout was imminent. Moreau’s ultimate excuse thereafter was “What If We Had Not…” ran a study for COVID-19?
The guy truly believes he can do no wrong…no wrong that he will ever be held accountable for.
What if management had not run an unpowered study for COVID-19?
The Answer Is Simple:
The company would not have been driven straight over a cliff into the Abyss.
The company would have retained the cash for the Phase 1’s in the pipeline now.
It’s the primary reason for a 100 to 1 reverse split and capital raise at All-time lows.
https://www.scribbr.com/statistics/statistical-power/ -
Just so we’re all clear here. The pattern of news release events prior to imminent data is playing out in the same way it did to the run up to COVID-19 Topline data. At that time management put out news releases stating the following:
January 19, 2021
The UK has not approved Algernon's Phase 1 DMT study
In this one instance I agree with tcm55. There is nothing in writing that suggests a DMT study has been given the go ahead to start in the UK. To my knowledge the application process is a 60 to 90 day window for approval. Algernon filed an application back in January 2022 (more than 150 days ago) and have not updated the public on it's status since. Instead, you are being dangled around the supposed start of DMT in Q3 2022. A timeline that's continued to get pushed back 1 2 3 quarters at a time. The stupidity never ends with how management communicates with shareholders. It's always some level of Smoke & Mirrors involved in everything coming out of the CEO's virtual office. Be it in writing or verbal. Any money raised by the clown team in the latest bomb fire sale of shares and warrants should go to getting results from a Phase 2 Chronic Cough clinical trial conducted in North America ASAP - results from start to finish within 12 months. We know it's possible because Bellus Health did it for it's shareholders. Aggressive timeline versus weak and fickle Christopher Moreau's decisions. Without it, you will continue suffering massive dilution and slow rolled data studies in other far away countries where he will attempt to lay the blame for a slow train to any data readouts. Moreau loves pointing the finger at everyone and everything else for his transparent ignorance at the helm of a publicly traded company. Christopher Moreau continues to make deals with the devil year after year with your money burning in his hands and burning a hole in your pocket.
Have @ it
M$
All That Jazz & Math
9 Million USD is a paltry number to raise capital on Wall Street. If you've paid any attention you realize Wall Street simply ain't buying what Algernon is peddling nowadays. Hence, "management" is now hat in hand at CSE penny world.
Your logic suggests people scrounging for pennies in-between their couch cushions is the best group of would-be investors equipped to raise 9M. So 9M is EZ money for the masses of little money trading on CSE versus magic money from the 24 carat yellow brick road - Land Of Oz?
Yeah...ok.
The Market Cap has dropped because the story continues to fall apart. Have you followed and understood the F-1 filings at SEC? The offering continues to drop like a rock. Thus, bonehead management will increase dilution by multiples which now includes matching warrants.
You keep talking about approvals this and that. Approvals for what? To my knowledge they are not waiting for anything but money. Must the FDA approve of tiny trials outside of the USA? Trials that likely will never be run in North America at any phase of the process? Algernon's business model is about running dirt cheap studies in countries with slow rolled enrollment for maximum dilution opportunities, including second world countries where fires break out at sites where all your data is stored.
In regards to the ongoing drumbeat about "averaging down" and expecting losses and all that jazz…how about telling that story-line to this poster here:
You’ll Get No Rainbows & Unicorns Here
Wall Street has rejected Algernon’s latest business strategy requiring a measly $9M in capital to launch.
If any of the clinical trials in the pipeline spelled fast turnaround investment dollars as you suggest, Moreau would not be right back at Pimp Smack Mackie bending over backwards to make another deal with the devil.
Two things glaringly (like warning lights) come to mind when I think of all the happy talk about Algernon since they torched the FAIMS deal:
"Everybody Wants In At Phase 2" - Christopher Moreau
"We Have A 65% Chance Of Success Because Safety Is Not An Issue" - Christopher Moreau (CEO) & Dr. Mark Williams (CSO).
Moreau & Con-pany will tell you ANYTHING (AS SEEN LIVE ON WEBCAST) to continue selling cheap shares to support their lifestyles.
Dr. Mark Williams even bailed out of Algernon to launch his own biotech company. Only to return not as the Chief Science Officer, but as a Director now void of being the point man for burning the midnight oil to cook the books with repurposed drugs theories.
Let Moreau tell it, Doc Williams adds a "secret sauce" to how he comes up with his repurposed drugs theories. Apparently Doc Williams has enough secret sauce to spread around for his personal cook book as well at Marvel Biosciences.
Chase the lies upon lies all you want. I'm only here now for the long drawn out data readout of 20 people with zero chance of statistical significance.
Let's watch how Andre Uddin spins this next Topline report since he's now on the payroll of Algernon. Is he going to trash the report and further crash the stock like he did the last time?
There's so much interwoven shenanigans to the Algernon story it would be impossible for a newbie to catch up to this ongoing soap opera starring Drama Queen Christopher Moreau.
Yet, you have the same common shareholder bending over backwards to justify all the wrong they see right before their eyes. Pure denial is a new phenomenon sweeping the globe like the plague. A common sense set of facts can no longer be had for the common good.
As I previously stated, Wall Street rejected the repurposed drugs plan hat in hand. They are experts at what they do. Do we have any experts here? No, we have bag holders who have been overwhelmed by sheer incompetency, legalized corruption (thank you CSE and OTC penny world), lies and more lies, continuous unfortunate surprises, reverse splits and dilution that is burying us all alive.
Yeah, keep giving me more of all of that at Phase 1 now.
Furthermore, when I speak of a 1 Trick Pony in my last post, I am specifically talking about the DMT angle for Stroke. If you look around for the true contenders (at least that’s what the overall market believes) in the psychedelic space, they all have multiple approaches to psychedelic treatments.
The ATAI’s - the Compass Pathways - the Cybin’s - the Mindmeds - even GHRS has 2 angles for its DMT drug. Algernon has an incredibly unlikely path to success with a Hail Mary for brain surgery. It makes for a good story but unfortunately one that Wall Street ain’t buying.
Shell says look at the ETF’s. Ok…and? Algernon has already participated in the Horizons ETF:
https://www.horizonsetfs.com/horizons/media/pdfs/pressreleases/2021/20210326_PSYKRebalance.pdf
The next horizon for Algernon is another steep cliff that will leave you flat in no time flat.
The “reorganization” of Algernon Pharmaceuticals was merely a whitewash to bury past incompetence and lies and presplt common shareholders. They assume you don't understand math and will simply go along with having gotten buried under a ton of newly issued shares and warrants. You're not understanding that every share sold moving forward represents 100 shares you held before the reverse split. The orchestrated capital raise on the CSE are shares being sold for 3 CENTS WITH A WARRANT. 3 CENTS. You need $30 on average to break even with pre split shares. Do you truly believe the cast of characters at Algernon is capable of turning Algernon into a multi-billion dollar company in your lifetime? By the time they’re done running their tiny Phase 1’s and Phase 2’s (not powered for stat sig) in slow rolled countries like Australia they will have run the outstanding shares north of 100 million and some shareholders will likely be dead and gone. Algernon is merely a stock selling scheme to support Moreau and friends lifestyles. Moreau thinks he’s a real catch. See him in his plunging necklines devoid of a tie all the time. Surely it goes well with being bent over the railing of someone's yacht in the Cayman Islands and elsewhere.
To Hell Is Where The Lot Of Them Are Headed!
^ That’s One Thing I’d Bet The Farm On Moving Forward >
Have @ it
M$
Postscript
tcm55